Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABSI Absci Corporation.

Closed 08-26 16:00:00 EDT

9.22

-0.41

-4.26%

盘后9.29

+0.07+0.76%

19:52 EDT

High9.65	Low8.90	Vol2.68M
Open9.56	D1 Closing9.63	Amplitude7.79%
Mkt Cap1.58B	Tradable Cap1.44B	Total Shares171.61M
T/O24.64M	T/O Rate1.71%	Tradable Shares156.49M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABSI","market":"US","secType":"STK","nameCN":"Absci Corporation.","latestPrice":9.22,"timestamp":1787774400000,"preClose":9.63,"halted":0,"volume":2676725,"hourTrading":{"tag":"盘后","latestPrice":9.29,"preClose":9.22,"latestTime":"19:52 EDT","volume":34666,"amount":319831.7164,"timestamp":1787788362508,"change":0.07,"changeRate":0.007592,"amplitude":0.008677},"delay":0,"changeRate":-0.042575285565939786,"floatShares":156491374,"shares":171614010,"eps":-0.799886,"marketStatus":"Closed","change":-0.41,"latestTime":"08-26 16:00:00 EDT","open":9.555,"high":9.65,"low":8.9,"amount":24638445.25405,"amplitude":0.077882,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.799886,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787817600000},"marketStatusCode":5,"adr":0,"listingDate":1626926400000,"exchange":"NASDAQ","adjPreClose":9.63,"preHourTrading":{"tag":"盘前","latestPrice":9.51,"preClose":9.63,"latestTime":"09:29 EDT","volume":2399,"amount":23032.357584,"timestamp":1787750999999,"change":-0.12,"changeRate":-0.012461,"amplitude":0.028037},"postHourTrading":{"tag":"盘后","latestPrice":9.29,"preClose":9.22,"latestTime":"19:52 EDT","volume":34666,"amount":319831.7164,"timestamp":1787788362508,"change":0.07,"changeRate":0.007592,"amplitude":0.008677},"volumeRatio":0.934886,"optionData":{"bulkOrders":[{"symbol":"ABSI","call":true,"expireDate":1832043600000,"strike":"3.0","timestamp":1787753045153,"price":6.8,"volume":1500,"amount":1020000,"type":"+"}]},"impliedVol":1.0538,"impliedVolPercentile":0.4064},"requestUrl":"/m/hq/s/ABSI/wiki","defaultTab":"wiki","newsList":[{"id":"2661245946","title":"How Positive ABS-201 Phase 1 Data And Pipeline Momentum At Absci (ABSI) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2661245946","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661245946?lang=en_us&edition=fundamental","pubTime":"2026-08-24 01:18","pubTimestamp":1787505483,"startTime":"0","endTime":"0","summary":"In August 2026, Absci Corporation reported positive interim Phase 1 data from its HEADLINETM trial of ABS-201 for pattern hair loss, indicating a favorable safety profile and an estimated half-life of at least 65 days, while also reaffirming plans to advance the program into endometriosis and a Phase 2 trial in 2026.\nThese early results suggest ABS-201 could offer infrequent dosing and a differentiated, non-sex-steroid approach in two large, under-served indications, alongside emerging...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-absi/absci/news/how-positive-abs-201-phase-1-data-and-pipeline-momentum-at-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-absi/absci/news/how-positive-abs-201-phase-1-data-and-pipeline-momentum-at-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ABSI","BK4121","ARKG","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660480048","title":"AbSci (ABSI) Receives a Hold from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2660480048","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660480048?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:58","pubTimestamp":1786971496,"startTime":"0","endTime":"0","summary":"In a report released today, Sean Laaman from Morgan Stanley maintained a Hold rating on AbSci, with a price target of $10.00. According to TipRanks...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/absci-absi-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/absci-absi-receives-a-hold-from-morgan-stanley-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ARKG","BK4121","BK4139","ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659018860","title":"Analysts Are Bullish on Top Healthcare Stocks: Monopar Therapeutics Inc (MNPR), AbSci (ABSI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659018860","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659018860?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:30","pubTimestamp":1786566610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monopar Therapeutics Inc (MNPR) and AbSci (ABSI) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-monopar-therapeutics-inc-mnpr-absci-absi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","MNPR","BK4121","ABSI","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EAT","TAN","LAZR","CRWV","UAMY","STRO","DFTX","UFO","SMCI","LOCL","ALT","HRB","SVV","LQDA","CHTR","EROC","LUMA","PFGC","SLXN","TECH","TRMB","NTHI","NBIS","SMWB","DPRE","NCMI","SLNCF","OFAL","SMCL","CIEN","FSLR","SMMT","SLN","CORD","EGGY","TSHA","GAP","NBIX","OPLN","O","LITE","HUMA","TPL","CAVA","BETA","WXM","NBIZ","BIVI","ABSI","ANNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903561","title":"Absci Falls After Q2 Revenue Misses Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903561","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658903561?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:03","pubTimestamp":1786543410,"startTime":"0","endTime":"0","summary":"BUZZ-Absci falls after Q2 revenue misses estimates** Shares of drug developer AbsciABSI.Ofall 1.4% to $9.3** Co posts Q2 revenue of $318,000, sharply below analysts' estimates of $1.2 mln** Reports increase in R&D expenses of $22.6 mln compared to $20.5 mln last year, primarily driven by advancement of ABSI's internal programs** Brokerage TD Cowen says revenue is expected to nearly halve due to lower collaboration and milestone payments, underscoring its reliance on partner-funded revenue** Says investors are pivoting the attention to its ABS-201 hair-loss data expected later this year- TD Cowen** Nine of 10 brokerages rate the stock \"buy\" or higher and one \"hold\"; median PT is $14- LSEG data** Including session's move, stock has more than doubled in value, YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4121","ABSI","BK4139","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197425","title":"AbSci (ABSI) Gets a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197425","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197425?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:36","pubTimestamp":1786534594,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kambiz Yazdi from BTIG maintained a Buy rating on AbSci, with a price target of $13.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/absci-absi-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/absci-absi-gets-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABSI","ARKG","BK4539","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976300","title":"Absci Price Target Maintained with a $13.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976300","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976300?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:08","pubTimestamp":1786529280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ABSI/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4121","ARKG","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658221945","title":"Absci Corp Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658221945","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658221945?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:01","pubTimestamp":1786482101,"startTime":"0","endTime":"0","summary":"Absci Corp reports results for the quarter ended June 30 - Earnings SummaryAbsci CorpABSI.OQreported a quarterly adjusted loss of 21 cents per share for the quarter ended June 30, higher than the same","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N448268:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABSI","BK4139","BK4121","BK4539","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945660","title":"Absci Q2 Loss Narrows, Revenue Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945660","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945660?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:43","pubTimestamp":1786480982,"startTime":"0","endTime":"0","summary":"Absci  reported a Q2 net loss late Tuesday of $0.21 per share, narrowing from a loss of $0.24 a year earlier.Analysts polled by FactSet expected a loss of $0.19.Revenue for the quarter ended June 30 fell to $318,000 from $593,000 a year earlier.Analysts expected $900,000.Shares of Absci were down more than 13% in after-hours trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARKG","BK4121","BK4139","ABSI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943272","title":"Absci Merilis Presentasi Korporat Tentang Platform AI Generatif Untuk Penciptaan Obat Dan Pengembangan ABS-201 Untuk Kerontokan Rambut Pola","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943272?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:30","pubTimestamp":1786480234,"startTime":"0","endTime":"0","summary":"Absci merilis presentasi korporat tentang platform AI generatif untuk penciptaan obat dan pengembangan ABS-201 untuk kerontokan rambut polaAbsci Corporation menegaskan fokus pada platform generatif AI","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL39rVf7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ARKG","ABSI","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943105","title":"Earnings Flash (ABSI) Absci Posts Q2 Loss $0.21, vs. FactSet Est of $0.19 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943105","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943105?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:20","pubTimestamp":1786479649,"startTime":"0","endTime":"0","summary":"Earnings Flash (ABSI) Absci Posts Q2 Loss $0.21, vs. FactSet Est of $0.19 Loss","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658338943","title":"Absci Q2 Revenue Falls and Misses Analyst Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2658338943","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658338943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:14","pubTimestamp":1786479256,"startTime":"0","endTime":"0","summary":"Absci Q2 revenue falls and misses analyst expectationsOverviewUS biopharma firm's Q2 revenue fell and missed analyst expectationsNet loss widened as R&D expenses rose due to advancing internal program","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4139","ARKG","ABSI","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948748","title":"Absci Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $318.000K Miss $1.169M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948748","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948748?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:08","pubTimestamp":1786478921,"startTime":"0","endTime":"0","summary":"Absci (NASDAQ:ABSI) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is a 12.5 percent increase over losses of $(0.24) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61126214/absci-q2-eps-0-21-misses-0-20-estimate-sales-318-000k-miss-1-169m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Absci Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $318.000K Miss $1.169M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABSI","BK4139","BK4121","ARKG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948495","title":"Absci Q2 Operating Income USD -34.158 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948495","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948495?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:06","pubTimestamp":1786478761,"startTime":"0","endTime":"0","summary":"BRIEF-Absci Q2 Operating Income USD -34.158 MillionAug 11 (Reuters) - Absci Q2 net income USD -33.21 million.Q2 operating expenses USD 34.476 millionQ2 basic EPS USD -0.21Q2 revenue USD 318 thousand vs. IBES estimate USD 1.17 millionQ2 pretax profit USD -33.17 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXP8JG9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARKG","ABSI","BK4121","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948691","title":"Absci Q2 Revenue USD 318 Thousand VS. Ibes Estimate USD 1.17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948691?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXP8JG9N:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","ARKG","ABSI","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948610","title":"Absci Q2 Operating Expenses USD 34.476 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948610","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948610?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478702,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXP8JG9N:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","ARKG","ABSI","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948282","title":"Press Release: Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948282","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948282?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478700,"startTime":"0","endTime":"0","summary":"Announced positive interim Phase 1 data from the HEADLINE trial of ABS-201Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & CompanyCash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026  -- Absci Corporation , a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.\"The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for what comes next,\" said Sean McClain, Founder and CEO. \"We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027. These results have the potential to demonstrate ABS-201's regenerat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","ABSI","BK4588","BK4139","BK4604","VTHR","AIPO","BK4099","CHAT","BK4121","BK4555","ARTY","ARKG","TM","KBWY","BK4181","AGIX","QTOC","BK4585","PK","BK4218","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999995","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999995","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999995?lang=en_us&edition=fundamental","pubTime":"2026-08-11 18:00","pubTimestamp":1786442400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·CAVA Grp Inc                                    2Q       .18   4:10 PM. ·Chicago Atl RE                                  2Q       .48   7:00 AM. ·Flowco Hldgs A                                  2Q       .38   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","CDNL","ALT","AUTL","BWAY","ABSI","BEEP","AVEX","AOSL","BTGO","ABOS","FEMY","ATRO","ALLT","AMBQ","BORR","CAE","SMCI","COHR","DDI","ATAI","AMCR","BCAX","CCCC","CRNT","BGSI","ARMK","AADX","CRWV","LITE","ANDG","CSCO","CURI","CAVA","BAK","BWEN","AII","BOLT","LIF","CDXS","ALLO","CINT","BETA","CBRS","BRCB","AQST","BGS","BHST","CAH","ATEX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657293016","title":"Absci Files Form 3 for CMO, Head of R&D Somaratne Ransi Mudalinayake","url":"https://stock-news.laohu8.com/highlight/detail?id=2657293016","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657293016?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:54","pubTimestamp":1786136059,"startTime":"0","endTime":"0","summary":"Absci files Form 3 for CMO, Head of R&D Somaratne Ransi MudalinayakeAbsci filed an initial beneficial ownership statement for Somaratne Ransi Mudalinayake, chief medical officer, head of R&D.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL3XZzYr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ABSI","ARKG","BK4121","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657625771","title":"Absci Corp Expected to Post a Loss of 20 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657625771","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657625771?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:02","pubTimestamp":1786132945,"startTime":"0","endTime":"0","summary":"Absci Corp <ABSI.OQ> expected to post a loss of20cents a share - Earnings PreviewAbsci CorpABSI.OQABSI.Ois expected to  show a rise in quarterly revenue when it reports  results on August 11 for the p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ARKG","BK4139","BK4539","ABSI"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.absci.com;investors.absci.com","stockEarnings":[{"period":"1week","weight":0.0881},{"period":"1month","weight":0.2738},{"period":"3month","weight":0.8663},{"period":"6month","weight":2.427},{"period":"1year","weight":2.7913},{"period":"ytd","weight":1.7593}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. It has a collaboration with Memorial Sloan Kettering Cancer Center to discover novel therapeutics using generative AI; with AstraZeneca PLC for AI-driven drug discovery against an oncology target; and with Twist Bioscience Corporation to design a novel therapeutic using generative AI. The company was founded in 2011 and is headquartered in Vancouver, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.106318},{"month":2,"riseRate":0.6,"avgChangeRate":0.064917},{"month":3,"riseRate":0.4,"avgChangeRate":-0.085447},{"month":4,"riseRate":0.4,"avgChangeRate":0.03426},{"month":5,"riseRate":0.4,"avgChangeRate":0.033031},{"month":6,"riseRate":0.2,"avgChangeRate":0.025606},{"month":7,"riseRate":0.6,"avgChangeRate":0.127868},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.070054},{"month":9,"riseRate":0.2,"avgChangeRate":-0.114873},{"month":10,"riseRate":0.8,"avgChangeRate":0.133791},{"month":11,"riseRate":0.2,"avgChangeRate":-0.134033},{"month":12,"riseRate":0.4,"avgChangeRate":0.218437}],"exchange":"NASDAQ","name":"Absci Corporation.","nameEN":"Absci Corporation."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Absci Corporation.,ABSI,Absci Corporation.股票,Absci Corporation.股票老虎,Absci Corporation.股票老虎国际,Absci Corporation.行情,Absci Corporation.股票行情,Absci Corporation.股价,Absci Corporation.股市,Absci Corporation.股票价格,Absci Corporation.股票交易,Absci Corporation.股票购买,Absci Corporation.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Absci Corporation.(ABSI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Absci Corporation.(ABSI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}